ATLANTA, Nov. 3, 2025 /PRNewswire/ -- Ambetter from Peach State Health Plan, a product offered by a Centene Corporation (NYSE: CNC) company, a leading healthcare enterprise that provides insurance to under-insured and uninsured populations through the Health Insurance Marketplace®, will offer a variety of affordable health insurance plans to Georgians in 149 counties for plan year 2026. The open enrollment period for the Health Insurance Marketplace runs from Nov. 1, 2025, through Jan. 15, 2026. Enroll by Dec. 15, 2025, for coverage starting Jan. 1, 2026.
"Our mission is to ensure that every Georgian can choose healthcare coverage that fits their needs and supports their health journey," said Plan President and Chief Executive Officer of Peach State Health Plan, Clyde White. "With enhanced benefits, innovative solutions and tools for enrollment and care, we're making it easier for individuals and families to take control of their health."
Ambetter from Peach State Health Plan offers its members access to quality care and convenient services. 2026 benefits and offerings include:
The full list of 149 counties in which Ambetter from Peach State Health Plan will be offered can be found at ambetterhealth.com/en/ga/health-plans/coverage-map.
Georgia residents interested in learning more about Ambetter from Peach State Health Plan or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/ga.
About Ambetter from Peach State Health Plan
Ambetter from Peach State Health Plan serves under-insured and uninsured populations through Georgia Access. Ambetter from Peach State Health Plan is underwritten by Ambetter of Peach State, Inc., which is a Qualified Health Plan issuer in Georgia. Ambetter Health, offering the Ambetter Health Solutions product, is underwritten by Peach State Health Plan, Inc. For more information, visit ambetterhealth.com/en/ga/. This is a solicitation for insurance. For information on your right to receive an Ambetter from Peach State Health Plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.

| Last Trade: | US$35.56 |
| Daily Change: | 1.06 3.07 |
| Daily Volume: | 4,800,203 |
| Market Cap: | US$17.480B |
October 29, 2025 July 29, 2025 July 25, 2025 April 25, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load